Weekly Topotecan Therapy in Patients With Ovarian Cancer
Status and phase
Conditions
Treatments
Details and patient eligibility
About
The purpose of this study is to find out the safety and feasibility of weekly topotecan consolidation therapy in patients with ovarian cancer.
Full description
Patients with Stage IIIC and IV optimally-debulked ovarian cancer will be treated with 6 cycles (every 3 weeks) of carboplatin (AUC 5) and paclitaxel (175 mg/m2). Patients who demonstrate a complete clinical response to this regimen will then be treated with topotecan consolidation (4 mg/m2 weekly x 8 weeks for one cycle followed by a break in the 9th week) for a maximum of 3 cycles. Primary endpoints will be toxicity and the determination of the appropriate dose, schedule, and duration of topotecan for further consolidation trials.
Sex
Ages
Volunteers
Inclusion criteria
- Patients must have a histopathologic diagnosis of epithelial ovarian cancer.
- Patients must have completed front-line chemotherapy and be clinically NED (CA 125 <35, negative CT scan, negative physical exam).
- Patients may have a second look laparoscopy, however, there must be no gross disease present (microscopic disease or pathologically negative).
- Patients must not have had other myelosuppressive therapy within four weeks of initiating topotecan therapy.
- Topotecan treatment must begin within 10 weeks following last cycle of initial chemotherapy.
- Patients may have had only one prior chemotherapy regimen.
Exclusion criteria
- Patients with a concomitant malignancy other than squamous cell or basal cell skin cancer.
- Patients who are pregnant or breast-feeding.
Trial design
Primary purpose
Allocation
Interventional model
Masking
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal